Next Article in Journal
A Study on the Epidemiological-Molecular Role of Staphylococcus aureus Strains in the Development of Ventilator-Associated Pneumonia in a Tertiary Hospital in Brazil
Previous Article in Journal
Antimicrobial Effect of Low-Fluoride Toothpastes Containing Polyphosphate and Polyols: An In Vitro Assessment of Inhibition Zones
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Antibiotics
Volume 12
Issue 8
10.3390/antibiotics12081335
antibiotics-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Ciprofloxacin and Tetracycline Resistance Cause Collateral Sensitivity to Aminoglycosides in Salmonella Typhimurium

by
Mahadi Hasan
1,
Jun Wang
2 and
Juhee Ahn
1,3,*
1
Department of Biomedical Science, Kangwon National University, Chuncheon 24341, Gangwon, Republic of Korea
2
College of Food Science and Engineering, Qingdao Agricultural University, Qingdao 266109, China
3
Institute of Bioscience and Biotechnology, Kangwon National University, Chuncheon 24341, Gangwon, Republic of Korea
*
Author to whom correspondence should be addressed.
Antibiotics 2023, 12(8), 1335; https://doi.org/10.3390/antibiotics12081335
Submission received: 25 July 2023 / Revised: 9 August 2023 / Accepted: 16 August 2023 / Published: 18 August 2023
(This article belongs to the Section Mechanisms and Structural Biology of Antibiotic Action)
Browse Figures
Versions Notes

Abstract

:
The objective of this study was to evaluate collateral sensitivity and cross-resistance of antibiotic-induced resistant Salmonella Typhimurium to various antibiotics. S. Typhimurium ATCC 19585 (STWT) was exposed to ciprofloxacin, gentamicin, kanamycin, and tetracycline to induce antibiotic resistance, respectively, assigned as STCIP, STGEN, STKAN, and STTET. The susceptibilities of the antibiotic-induced resistant mutants to cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, polymyxin B, streptomycin, tetracycline, and tobramycin were determined in the absence and presence of CCCP and PAβN. STCIP showed the cross-resistance to tetracycline and collateral sensitivity to gentamicin (1/2 fold) and kanamycin (1/4 fold). STTET was also cross-resistant to ciprofloxacin (128-fold) and collateral sensitive to gentamicin (1/4-fold) and kanamycin (1/8-fold). The cross-resistance and collateral sensitivity of STCIP and STTET were associated with the AcrAB-TolC efflux pump and outer membrane porin proteins (OmpC). This study provides new insight into the collateral sensitivity phenomenon, which can be used for designing effective antibiotic treatment regimens to control antibiotic-resistant bacteria.

1. Introduction

Salmonella is a major foodborne pathogen that causes widespread contamination and infections [1]. One of the main serovars that cause human and animal salmonellosis is Salmonella Typhimurium [2]. It has been reported to cause 115 million human infections and 370 thousand deaths per year on a global scale [3]. Severe Salmonella infections require antibiotic intervention; however, antibiotic resistance in Salmonella Typhimurium presents yet another challenge to overcome [2]. Overuse, misuse, and extensive application of antibiotics in clinics and livestock sectors are putting constant selection pressure on the bacteria population, thus giving rise to resistance in pathogenic bacteria, including S. Typhimurium [4,5]. Worryingly, the emergence of antibiotic-resistant bacteria is much more frequent than the discovery rates of novel antibiotics [6]. In fact, no new class of antibiotics has been discovered in the last two decades despite substantial efforts. Because of the limited effective antibiotic options available, a rational application strategy of existing antibiotics should be considered with a particular emphasis on suppressing or reversing resistance evolution in pathogenic bacteria [7].
The emergence of cross-resistance in pathogenic bacteria has far-reaching consequences. The cross-resistance occurs when the development of resistance to one antibiotic causes an increase in resistance to another antibiotic in the same class or even against different classes of antibiotics [8]. This phenomenon occurs due to acquired resistance mechanisms, such as genetic mutations of the target site, reduced uptake of the antibiotics, and increased efflux pumps, which confer resistance to one antibiotic and can also confer resistance to other antibiotics with similar structure, function, or target site [9]. The selection of appropriate therapeutic options is severely constrained by this cross-resistance, which in turn renders an increasing number of antibiotics ineffective at treating infections [8,10].
The mechanisms underlying cross-resistance in bacteria are diverse and complex, including efflux pumps, horizontal gene transfer, genetic mutations, and altered target sites [8]. Efflux pumps play an active role in exporting drugs, thereby preventing the accumulation of drugs within the cell, and may cause resistance to multiple antibiotics. Moreover, the induced resistance under the selection pressure of cefotaxime and azithromycin has been reported to cause cross-resistance through AcrB, a component of the AcrAB-TolC tripartite efflux pump system [11]. Similarly, cross-resistance can occur when OmpC is downregulated, as antibiotics from diverse classes enter bacteria through this outer membrane porin [12].
Antibiotic collateral sensitivity is a phenomenon in which resistance to one antibiotic leads to increased susceptibility or hypersensitivity to a different, often structurally unrelated, antimicrobial agent [13]. Unlike antibiotic cross-resistance, collateral sensitivity provides a counterintuitive advantage by capitalizing on bacterial vulnerabilities caused by resistance acquisition [14]. This phenomenon has important implications for antimicrobial research and may open up new avenues for novel therapeutic strategies. Antibiotic collateral sensitivity mechanisms are also diverse and complex [15]. Genetic mutation or modification of bacterial cellular components that confer antibiotic resistance can make the pathogen more susceptible to another. These mutations may disrupt cellular functions, metabolic pathways, or efflux pump systems, resulting in a cascade response of downstream effects that make the bacterium more susceptible to a different antibiotic [14]. Furthermore, changes in bacterial physiology, such as cell membrane permeability or drug target expression, can influence antibiotic collateral sensitivity [15].
Utilizing the potential role of collateral sensitivity in therapies such as combination therapy and alternating therapy can potentially be a successful way to suppress the evolution of resistance or alter the resistance profile [16]. The potential application mechanisms of collateral sensitivity have been studied on several clinically relevant pathogens, including Escherichia coli [17,18,19], Pseudomonas aeruginosa [20,21], Enterococcus faecalis [22], streptococcus pneumoniae [23], Staphylococcus aureus [24], and Klebsiella pneumoniae [15]. For example, the induction of aminoglycoside resistance has been reported to cause increased sensitivity to other classes of antibiotics such as β-lactams, fluoroquinolones, chloramphenicol, tetracyclines, and doxycycline [15,19]. However, such a study on S. Typhimurium is very scarce. Therefore, the study was aimed to evaluate the collateral sensitivity and cross-resistance of ciprofloxacin-, gentamicin-, kanamycin-, and tetracycline-induced resistant Salmonella Typhimurium ATCC 19585 to cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, polymyxin B, streptomycin, tetracycline, and tobramycin (Table 1).

2. Results

2.1. Cross-Resistance and Collateral Sensitivity of Antibiotic-Induced Resistant S. Typhimurium

In order to identify cross-resistance and collateral sensitivity, the antibiotic-induced resistant mutants of S. Typhimurium ATCC 19585 (STWT) were induced by exposure to ciprofloxacin (CIP), gentamicin (GEN), kanamycin (KAN), and tetracycline (TET), assigned as STCIP, STGEN, STKAN, and STTET, respectively. The antibiotic susceptibility of the induced resistant mutants was determined using cefotaxime, chloramphenicol, ciprofloxacin, gentamicin, kanamycin, polymyxin B, streptomycin, tetracycline, and tobramycin (Table 2). The antibiotic-induced resistant mutants were highly resistant to ciprofloxacin (1024-fold), gentamicin (8-fold), kanamycin (8-fold), and tetracycline (8-fold), respectively.
A heatmap was created to represent the fold change in MICs of STCIP, STGEN, STKAN, and STTET, highlighting both cross-resistance and collateral sensitivity in relation to the wild type across diverse classes of antibiotics (Figure 1). STCIP was cross-resistant to cefotaxime, chloramphenicol, and tetracycline, STGEN was cross-resistant to chloramphenicol, kanamycin, streptomycin, and tobramycin, STKAN was cross-resistant to cefotaxime, chloramphenicol, gentamicin, streptomycin, and tobramycin, and STTET was cross-resistant to cefotaxime, chloramphenicol, and ciprofloxacin. Surprisingly, STCIP showed increased susceptibility, and collateral sensitivity, to gentamicin, kanamycin, streptomycin, and tobramycin, STGEN showed collateral sensitivity to ciprofloxacin, polymyxin B, and tetracycline, STKAN showed collateral sensitivity to polymyxin B and tetracycline, and STTET showed collateral sensitivity to gentamicin, kanamycin, streptomycin, and tobramycin. The MIC values of polymyxin B, cefotaxime, ciprofloxacin, and polymyxin B remained unchanged for STCIP, STGEN, STKAN, and STTET.

2.2. Role of Antibiotic Resistance Mechanisms in Evolving cross-Resistance and Collateral Sensitivity

The MIC values of ciprofloxacin, gentamicin, kanamycin, and tetracycline, respectively, against STCIP, STGEN, STKAN, and STTET in the absence and presence of carbonyl cyanide-m-chlorophenylhydrazone (CCCP) and phenylalanine-arginine-β-naphthylamide (PAβN) were determined to evaluate the effect of efflux pumps (Table 3). The MIC of ciprofloxacin against STCIP, gentamicin against STGEN, and kanamycin against STKAN remained unchanged regardless of the presence or absence of CCCP, while the tetracycline resistance of STTET was increased in the presence of CCCP. Unlike CCCP treatment, the susceptibility of STCIP to ciprofloxacin was increased in the presence of PAβN. No changes in antimicrobial activities of gentamicin, kanamycin, and tetracycline were observed against STGEN, STKAN, and STTET.
The relative expression levels of efflux pump- and porin-associated genes were observed in the antibiotic-induced resistant mutants (Figure 2). The relative expression levels of acrA, acrB, ramA, and tolC were increased in STCIP. The genes acrA, acrB, ompC, ramA, and tolC, were suppressed more than 10-fold in STTET.

3. Discussion

Bacterial adaptation to a single antibiotic under antibiotic selection pressure may result in enhanced sensitivity to other classes of antibiotics, steered by an evolutionary trade-off between underlying antibiotic resistance mechanisms, termed collateral sensitivity [25]. Collateral sensitivity was first described in the early 1950s by Szybalski and Bryson [26]. The experimentally evolved resistant E. coli isolates were less, equally, or more sensitive to antibiotics that were not used for the resistance induction [27]. Although cross-resistance is much more prevalent than collateral sensitivity in antibiotic-resistant bacteria, the phenomenon regarding the collateral sensitivity to antibiotics can provide a possibility of using antibiotics that increase the susceptibility to other antibiotics [14,15,27]. Therefore, collateral sensitivity and its underlying mechanisms have recently been studied in vitro and in vivo levels [15,19,20]. These studies include both Gram-positive bacteria, such as Staphylococcus aureus and Enterococcus faecium, and Gram-negative bacteria, such as E. coli and Klebsiella pneumoniae [15,19,28,29]. However, there have been relatively few studies to evaluate the collateral sensitivity in antibiotic-resistant S. Typhimurium [25,30].
The collateral sensitivity of bacteria is due to an antibiotic resistance mechanism that can provide a cooperative phenomenon to other classes of antibiotics [31]. For example, the efflux pump-mediated resistance requires increasing proton concentration as the component of proton motive force (PMF) in the bacterial periplasm [32]. On the other side, the penetration of antibiotics such as aminoglycosides into the bacteria is highly dependent on the transmembrane potential, another component of PMF [33]. Thus, the efflux pump-related resistance of bacteria to fluoroquinolone requires a reaching strong PMF, which can induce susceptibility to aminoglycosides. This phenomenon, collateral sensitivity, can possibly be used for re-sensitizing bacteria to antibiotics by reversing multidrug resistance. Ciprofloxacin is an appropriate substrate of AcrAB-TolC efflux pump. AcrAB-TolC, a tripartite resistance-nodulation-division (RND) efflux pump, confers resistance to a broad range of antibiotics [34]. The periplasmic lipoprotein, AcrA, is classified as a fusion protein that bridges the outer and inner membranes [35]. The AcrB is a membrane protein located in the cytoplasmic membrane, and the TolC is an outer membrane protein [36,37]. Together they form AcrAB-TolC tripartite efflux pump system (Figure 3A). This tripartite efflux pump actively extrudes toxic substances, including antibiotics, dyes, disinfectants, and detergents [38]. The efflux pump activity can be reduced by the addition of various natural and synthetic substances called efflux pump inhibitors (EPIs) [39]. CCCP and PAβN are most commonly used as EPIs for experimental purposes.
STCIP was highly resistant to ciprofloxacin, showing an MIC value of 16 µg/mL (Table 2). The MICs of ciprofloxacin against STCIP were the same in the absence and presence of CCCP (Table 3). In a recent report, it is found that CCCP might not always be an effective EPI [15]. This is in good agreement with our finding that CCCP did not show reduced efflux pump-mediated resistance (Table 3). Unlike CCCP, the MIC of ciprofloxacin against STCIP was decreased in the presence of PAβN (Table 3). PAβN is a synthetic efflux pump inhibitor that counteracts the activity of RND family efflux pumps [40]. The modified dipeptide-amide inhibits antibiotic efflux through the AcrAB-TolC system [37]. A computational simulation showed that PAβN binds to AcrB and inhibits efflux pumps at several residues [41,42]. PAβN binds with the proximal substrate-binding site of AcrB to interrupt the antibiotic-AcrB complex formation [43]. The increased susceptibility of STCIP to ciprofloxacin in the presence of PAβN (Table 3) implies that STCIP has an RND efflux pump (AcrAB-TolC). Furthermore, the expression levels of acrA, acrB, and tolC were overexpressed in STCIP (Figure 2). The AcrAB-TolC efflux pump could actively extrude ciprofloxacin out of the bacterial cells, resulting in antibiotic resistance development [37]. The increase in ramA expression contributes to the enhanced efflux pump activity by regulating the expression of acrA, acrB, and tolC in Salmonella spp. [34]. However, the relative expression levels of acrA, acrB, ramA, and tolC were significantly decreased in STTET (Figure 2).
Tetracycline resistance was less mediated by the AcrAB-TolC efflux pump system than other antibiotic resistance in S. Typhimurium [44]. Conversely, the upregulation of AcrAB-TolC was associated with the development of tetracycline resistance in Klebsiella pneumoniae [15]. This implies the induction of cross-resistance to ciprofloxacin and tetracycline in antibiotic-resistant S. Typhimurium. AcrAB-TolC efflux pump requires PMF as an energy source to extrude antibiotics and other toxic components [39]. The increase in PMF contributed to the increase in bacterial susceptibility to kanamycin, an aminoglycoside antibiotic [45]. On the contrary, the reduced expression of cytochrome oxidases, which plays a vital role in the creation of PMF, induced low membrane potential, and high aminoglycoside resistance [15]. Cytochrome oxidases transport protons from cytoplasm to periplasmic space in the electron transport chain that oxidizes terminal electron acceptors such as oxygen to create PMF [46]. This may explain the increased susceptibility of STCIP to gentamicin and kanamycin in this study. In Gram-negative bacteria, tetracycline acts as an Mg2+ chelator by diffusing through OmpC and/or OmpF [47] (Figure 3B). The major outer membrane porin proteins, OmpC and OmpF, contribute to the accumulation of tetracycline inside the bacterial cells, leading to increased antibiotic susceptibility [48]. In this study, the decreased expression of ompC in STTET might be involved in the increase in tetracycline resistance (Table 2). The ciprofloxacin resistance was also associated with the low expression level of ompC in S. Typhimurium [49]. Furthermore, tetracycline-resistant Gram-negative bacteria were also sensitive to aminoglycosides, which is in good agreement with the finding of this study [15,19].
PMF consisting of transmembrane electrical potential (Δψ) and transmembrane proton gradient (ΔpH) plays a major role in aminoglycoside internalization into bacterial cells [33,50]. Bacteria maintain the electrochemical potential balanced by Δψ and ΔpH in the cytoplasmic membrane [50,51]. Thus, the perturbation of PMF may result in compensatory phenomena in bacteria [52]. The membrane potential-uncoupling antibiotics may collapse PMF due to the dissipation of Δψ or ΔpH [52]. Unlike ATP-binding cassette (ABC) transporter, the multidrug efflux pump families such as RND, small multidrug resistance (SMR), multidrug and toxic compound extrusion (MATE), and major facilitator superfamily (MFS) require PMF that is generated by cellular metabolism [53,54,55]. The perturbation of PMF can cause a decrease in the activity of PMF-dependent efflux pumps and result in an increase in antibiotic susceptibility [19]. A protonophore, CCCP, disrupts the PMF to reduce/abolish the activity of efflux pumps [40] (Figure 3C). The decrease in membrane potential, consequently PMF, is responsible for the increased resistance to aminoglycoside [15]. The cross-resistance of STGEN and STKAN to gentamicin and kanamycin and collateral sensitivity to ciprofloxacin and tetracycline may be attributed to PMF dissipation. The decreased PMF in STGEN and STKAN might decrease the activity of AcrAB-TolC, leading to increased sensitivity to ciprofloxacin and tetracycline.
It is important to recognize some limitations in our study of induced cross-resistance and collateral sensitivity in S. Typhimurium. First of all, whole-genome sequencing was not performed, which could have given a thorough understanding of the genetic basis of the observed changes in sensitivity and resistance. Due to this reason, the precise genetic mutations or modifications in metabolic pathways that may be responsible for these phenomena could not be addressed in this article. In addition, not all known potential resistance mechanisms were examined in the study. Numerous genetic, biochemical, and physiological factors may play a role in the complex process of antibiotic resistance in S. Typhimurium and can lead to the emergence of cross-resistance as well as collateral sensitivity. While some well-known mechanisms have been explored, there might be other potential mechanisms that were not investigated in this study. Despite the limitations, this study provides new useful information on antibiotic-induced cross-resistance and collateral sensitivity in S. Typhimurium. The results may serve as the foundation for follow-up research, which may include whole-genome sequencing and a thorough examination of antibiotic resistance mechanisms to gain a better understanding of the complexities of antibiotic resistance in S. Typhimurium. These studies would aid in the development of effective anti-antibiotic resistance strategies and enhance the treatment options for Salmonella infections.

4. Materials and Methods

4.1. Strain and Culture Conditions

Salmonella Typhimurium ATCC 19585 (STWT) was purchased from American Type Culture Collection (ATCC, Manassas, VA, USA). The strain was cultured for 18 h at 37 °C in trypticase soy broth (TSB; BD, Becton, Dickinson and Co., Sparks, MD, USA) supplemented with 0.1% yeast extract (TSBY). The culture was collected by centrifugation at 6000× g for 10 min at 4 °C. The harvested cells were then washed twice with phosphate-buffered saline (PBS, pH 7.2) prior to use.

4.2. Preparation of Antibiotic Stock Solutions

The antibiotics used in this study (Table 1) were purchased from Sigma Chemical Co. (St. Louis, MO, USA). The stock solutions of cefotaxime (water), chloramphenicol (ethanol), ciprofloxacin (glacial acetic acid), gentamicin (water), kanamycin (water), polymyxin B (water), tetracycline (ethanol), streptomycin (water), and tobramycin (water) were prepared by dissolving in appropriate solvents at a concentration of 10.24 mg/mL.

4.3. Induction of Antibiotic-Resistant Salmonella

STWT was used to induce antibiotic resistance to ciprofloxacin (STCIP), gentamicin (STGEN), kanamycin (STKAN), and tetracycline (STTET) according to a previous method [56] with slight modification. In brief, STWT was cultured in TSBY with 1/2×MIC of the above-mentioned antibiotics individually for the first passage. After 24–72 h of incubation at 37 °C, the cultures (200 µL each) were transferred to TSBY with A 2-fold increase in the concentration of the same antibiotic and then serially incubated at the same condition. This procedure was continued until no growth was observed after 72 h of incubation.

4.4. Antibiotic Susceptibility Assay

The effects of efflux pump inhibitor phenylalanine-arginine-β-naphthylamide (PAβN) and protonophore carbonyl cyanide-m-chlorophenylhydrazone (CCCP) on antibiotic susceptibility of STWT, STCIP, STGEN, STKAN, and STTET, were evaluated using a broth microdilution susceptibility assay according CLSI guideline [57]. In brief, approximately 105 CFU/mL of STWT and the antibiotic-induced resistant mutants were inoculated in the 96-well plates containing serially diluted (1:2) stock solutions from 1024 µg/mL in TSBY. The prepared plates were incubated at 37 °C for 18 h to determine MICs of antibiotics in the absence and presence of PAβN and CCCP.

4.5. RT-qPCR Assay

Total RNAs in STWT and the antibiotic-induced resistant mutants were extracted by using the RNeasy Protect Bacteria Mini kit (Qiagen, Hilden, Germany). The RNA extracts were mixed with 1 mL of RNAprotect Bacteria reagent (Qiagen) to prevent RNA degradation, centrifuged at 5000× g for 10 min, and then lysed by TE buffer containing lysozyme (1 mg/mL). The lysates were mixed with ethanol to purify RNA using an RNeasy mini column (Qiagen). The RNAs were quantified using a NanoDrop spectrophotometer. Complementary DNA (cDNA) was synthesized by transcribing RNA templates through QuantiTect Reverse Transcription kit (Qiagen). In brief, the purified RNA was reacted with a Wipe buffer to eliminate genomic DNA (gDNA). The reactants were mixed with a Reverse Transcriptase (RT) Master mix containing RT Buffer, RT Primer Mix, and Reverse Transcriptase. The mixtures were reacted for 15 min at 42 °C and inactivated at 95 °C for 3 min. The PCR mixture (20 μL) was prepared by mixing 2 μL of cDNA with 1.2 μL of reverse and forward primers, 10 μL of SYBR Green, and 5.6 μL of Nuclease-free water and reacted through a QuantStudio™ 3 Real-Time PCR System (Applied Biosystems™, MA, USA). The thermal cycling conditions for the qPCR assay were set at 45 cycles. The PCR mixture was denatured at 95 °C for 5 s, annealed at 55 °C for 20 s, and extended at 72 °C for 15 s. The primers, including reference gene, multidrug efflux pump, outer membrane porin, and transcriptional activator-associated genes, are listed in Table 4. The gene expression was relatively estimated by comparing Ct values according to the comparative method [58]. The expression levels of target genes (acrA, acrB, ompC, ompF, ramA, and tolC) in the antibiotic-induced resistant mutants relative to STWT cells were estimated and calculated using the formula; ΔΔCt = ΔCttreatment − ΔCtcalibrator. The ΔCttreatment is the Ct values for the antibiotic-induced resistant mutants were normalized to 16S rRNA (Cttreatment − Ct [16S rRNA]treatment), and the ΔCtcalibrator is the Ct values for the STWT cells normalized to 16S rRNA (Ctcalibrator − Ct [16S rRNA]calibrator). The comparative ΔΔCt method was validated by the amplification efficiencies of the respective target genes (acrA, acrB, ompC, ompF, ramA, and tolC) and the reference gene (16S rRNA).

5. Conclusions

Collateral sensitivity has important clinical implications and may transform the approach to antibiotic therapy. By strategically combining antibiotics with collateral sensitivity, it is possible to induce the enhanced susceptibility of bacteria to antibiotics, enhancing bacterial eradication and lowering the risk of resistance development. This concept has great potential not only in human medicine but also in veterinary and agricultural settings, where multidrug-resistant pathogens pose a significant threat to animal health and food production. This study describes cross-resistance and collateral sensitivity in STCIP, STGEN, STKAN, and STTET in association with the induction of antibiotic resistance. The most significant finding of this study was the collateral sensitivity of STCIP and STTET to gentamicin and kanamycin. STKAN showed no collateral sensitivity to ciprofloxacin. The efflux pumps, and outer membrane porin proteins were linked to the collateral sensitivity and cross-resistance. These results can be useful for designing effective antibiotic treatments, such as alternating and combination antibiotic treatments for infections caused by antibiotic-resistant bacteria. Further study is needed to investigate whole genome sequencing of the antibiotic-induced resistant mutants to elucidate the exact genetic alteration responsible for increased antibiotic susceptibility. In addition, a gene knockout and complementation study is underway in our lab to validate the mechanisms associated with collateral sensitivity.

Author Contributions

M.H. conducted all experiments and also wrote the manuscript, J.W. contributed to the data analysis, and J.A. designed the experiment, edited, reviewed the manuscript, and supervised. All authors have read and agreed to the published version of the manuscript.

Funding

This research was supported by the Basic Science Research Program through the National Research Foundation of Korea (NRF), funded by the Ministry of Education (NRF-2016R1D1A3B0100830416).

Institutional Review Board Statement

Not applicable.

Informed Consent Statement

Not applicable.

Data Availability Statement

Data available on request.

Conflicts of Interest

The authors declare no conflict of interest.

References

  1. Eng, S.-K.; Pusparajah, P.; Ab Mutalib, N.-S.; Ser, H.-L.; Chan, K.-G.; Lee, L.-H. Salmonella: A review on pathogenesis, epidemiology and antibiotic resistance. Front. Life Sci. 2015, 8, 284–293. [Google Scholar] [CrossRef]
  2. Wang, X.; Biswas, S.; Paudyal, N.; Pan, H.; Li, X.; Fang, W.; Yue, M. Antibiotic resistance in Salmonella Typhimurium isolates recovered from the food chain through national antimicrobial resistance monitoring system between 1996 and 2016. Front. Microbiol. 2019, 10, 985. [Google Scholar] [CrossRef]
  3. Seif, Y.; Kavvas, E.; Lachance, J.C.; Yurkovich, J.T.; Nuccio, S.P.; Fang, X.; Catoiu, E.; Raffatellu, M.; Palsson, B.O.; Monk, J.M. Genome-scale metabolic reconstructions of multiple Salmonella strains reveal serovar-specific metabolic traits. Nat. Commun. 2018, 9, 3771. [Google Scholar] [CrossRef]
  4. Uddin, T.M.; Chakraborty, A.J.; Khusro, A.; Zidan, B.M.R.M.; Mitra, S.; Emran, T.B.; Dhama, K.; Ripon, M.K.H.; Gajdács, M.; Sahibzada, M.U.K.; et al. Antibiotic resistance in microbes: History, mechanisms, therapeutic strategies and future prospects. J. Infect. Public Health 2021, 14, 1750–1766. [Google Scholar] [CrossRef]
  5. Dawan, J.; Ahn, J. Assessment of cooperative antibiotic resistance of Salmonella Typhimurium within heterogeneous population. Microb. Pathog. 2021, 157, 104973. [Google Scholar] [CrossRef]
  6. Roope, L.S.J.; Smith, R.D.; Pouwels, K.B.; Buchanan, J.; Abel, L.; Eibich, P.; Butler, C.C.; Tan, P.S.; Walker, A.S.; Robotham, J.V.; et al. The challenge of antimicrobial resistance: What economics can contribute. Science 2019, 364, eaau4679. [Google Scholar] [CrossRef]
  7. Murugaiyan, J.; Kumar, P.A.; Rao, G.S.; Iskandar, K.; Hawser, S.; Hays, J.P.; Mohsen, Y.; Adukkadukkam, S.; Awuah, W.A.; Jose, R.A.M.; et al. Progress in alternative strategies to combat antimicrobial resistance: Focus on antibiotics. Antibiotics 2022, 11, 200. [Google Scholar] [CrossRef]
  8. Sincak, M.; Šoltisová, K.; Luptakova, A.; Sedlakova-Kadukova, J. Overproduction of efflux pumps as a mechanism of metal and antibiotic cross-resistance in the natural environment. Sustainability 2023, 15, 8767. [Google Scholar] [CrossRef]
  9. Kavya, I.K.; Kochhar, N.; Ghosh, A.; Shrivastava, S.; Singh Rawat, V.; Mondal Ghorai, S.; Kaur Sodhi, K.; James, A.; Kumar, M. Perspectives on systematic generation of antibiotic resistance with special emphasis on modern antibiotics. Total Environ. Res. Themes 2023, 8, 100068. [Google Scholar]
  10. Dawan, J.; Ahn, J. Assessment of cross-resistance potential to serial antibiotic treatments in antibiotic-resistant Salmonella Typhimurium. Microb. Pathog. 2020, 148, 104478. [Google Scholar] [CrossRef]
  11. Trampari, E.; Prischi, F.; Vargiu, A.V.; Abi-Assaf, J.; Bavro, V.N.; Webber, M.A. Functionally distinct mutations within AcrB underpin antibiotic resistance in different lifestyles. npj Antimicrob. Resist. 2023, 1, 2. [Google Scholar] [CrossRef]
  12. Akshay, S.D.; Nayak, S.; Deekshit, V.K.; Rohit, A.; Maiti, B. Differential expression of outer membrane proteins and quinolone resistance determining region mutations can lead to ciprofloxacin resistance in Salmonella Typhi. Arch. Microbiol. 2023, 205, 136. [Google Scholar] [CrossRef] [PubMed]
  13. Aulin, L.B.S.; Liakopoulos, A.; van der Graaf, P.H.; Rozen, D.E.; van Hasselt, J.G.C. Design principles of collateral sensitivity-based dosing strategies. Nat. Commun. 2021, 12, 5691. [Google Scholar] [CrossRef] [PubMed]
  14. Hernando-Amado, S.; Laborda, P.; Martínez, J.L. Tackling antibiotic resistance by inducing transient and robust collateral sensitivity. Nat. Commun. 2023, 14, 1723. [Google Scholar] [CrossRef] [PubMed]
  15. Ma, X.; Xi, W.; Yang, D.; Zhao, L.; Yu, W.; He, Y.; Ni, W.; Gao, Z. Collateral sensitivity between tetracyclines and aminoglycosides constrains resistance evolution in carbapenem-resistant Klebsiella pneumoniae. Drug Resist. Uptat. 2023, 68, 100961. [Google Scholar] [CrossRef] [PubMed]
  16. Pál, C.; Papp, B.; Lázár, V. Collateral sensitivity of antibiotic-resistant microbes. Trends Microbiol. 2015, 23, 401–407. [Google Scholar] [CrossRef]
  17. Podnecky, N.L.; Fredheim, E.G.A.; Kloos, J.; Sørum, V.; Primicerio, R.; Roberts, A.P.; Rozen, D.E.; Samuelsen, Ø.; Johnsen, P.J. Conserved collateral antibiotic susceptibility networks in diverse clinical strains of Escherichia coli. Nat. Commun. 2018, 9, 3673. [Google Scholar] [CrossRef]
  18. Imamovic, L.; Sommer, M.O.A. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 2013, 5, 204ra132. [Google Scholar] [CrossRef]
  19. Lázár, V.; Pal Singh, G.; Spohn, R.; Nagy, I.; Horváth, B.; Hrtyan, M.; Busa-Fekete, R.; Bogos, B.; Méhi, O.; Csörgő, B.; et al. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 2013, 9, 700. [Google Scholar] [CrossRef]
  20. Barbosa, C.; Trebosc, V.; Kemmer, C.; Rosenstiel, P.; Beardmore, R.; Schulenburg, H.; Jansen, G. Alternative evolutionary paths to bacterial antibiotic resistance cause distinct collateral effects. Mol. Biol. Evol. 2017, 34, 2229–2244. [Google Scholar] [CrossRef]
  21. Barbosa, C.; Beardmore, R.; Schulenburg, H.; Jansen, G. Antibiotic combination efficacy (ACE) networks for a Pseudomonas aeruginosa model. PLoS Biol. 2018, 16, e2004356. [Google Scholar] [CrossRef] [PubMed]
  22. Maltas, J.; Wood, K.B. Pervasive and diverse collateral sensitivity profiles inform optimal strategies to limit antibiotic resistance. PLoS Biol. 2019, 17, e3000515. [Google Scholar] [CrossRef] [PubMed]
  23. Liakopoulos, A.; Aulin, L.B.S.; Buffoni, M.; Fragkiskou, E.; Hasselt, J.G.C.v.; Rozen, D.E. Allele-specific collateral and fitness effects determine the dynamics of fluoroquinolone resistance evolution. Proc. Natl. Acad. Sci. USA 2022, 119, e2121768119. [Google Scholar] [CrossRef] [PubMed]
  24. Kim, S.; Lieberman, T.D.; Kishony, R. Alternating antibiotic treatments constrain evolutionary paths to multidrug resistance. Proc. Natl. Acad. Sci. USA 2014, 111, 14494–14499. [Google Scholar] [CrossRef]
  25. Brepoels, P.; Appermans, K.; Pérez-Romero, C.A.; Lories, B.; Marchal, K.; Steenackers, H.P. Antibiotic cycling affects resistance evolution independently of collateral sensitivity. Mol. Biol. Evol. 2022, 39, msac257. [Google Scholar] [CrossRef] [PubMed]
  26. Szybalski, W.; Bryson, V. Genetic studies on microbial cross resistance to toxic agents. I. Cross resistance of Escherichia coli to fifteen antibiotics. J. Bacteriol. 1952, 64, 489–499. [Google Scholar] [CrossRef]
  27. Liu, D.Y.; Phillips, L.; Wilson, D.M.; Fulton, K.M.; Twine, S.M.; Wong, A.; Linington, R.G. Collateral sensitivity profiling in drug-resistant Escherichia coli identifies natural products suppressing cephalosporin resistance. Nat. Commun. 2023, 14, 1976. [Google Scholar] [CrossRef]
  28. Gonzales, P.R.; Pesesky, M.W.; Bouley, R.; Ballard, A.; Biddy, B.A.; Suckow, M.A.; Wolter, W.R.; Schroeder, V.A.; Burnham, C.A.; Mobashery, S.; et al. Synergistic, collaterally sensitive beta-lactam combinations suppress resistance in MRSA. Nat. Chem. Biol. 2015, 11, 855–861. [Google Scholar] [CrossRef]
  29. Harrison, E.M.; Ba, X.; Coll, F.; Blane, B.; Restif, O.; Carvell, H.; Koser, C.U.; Jamrozy, D.; Reuter, S.; Lovering, A.; et al. Genomic identification of cryptic susceptibility to penicillins and beta-lactamase inhibitors in methicillin-resistant Staphylococcus aureus. Nat. Microbiol. 2019, 4, 1680–1691. [Google Scholar] [CrossRef]
  30. Trampari, E.; Holden, E.R.; Wickham, G.J.; Ravi, A.; Martins, L.d.O.; Savva, G.M.; Webber, M.A. Exposure of Salmonella biofilms to antibiotic concentrations rapidly selects resistance with collateral tradeoffs. npj Biofilms Microbiomes 2021, 7, 3. [Google Scholar] [CrossRef]
  31. Roemhild, R.; Andersson, D.I. Mechanisms and therapeutic potential of collateral sensitivity to antibiotics. PLoS Pathog. 2021, 17, e1009172. [Google Scholar] [CrossRef] [PubMed]
  32. Le, D.; Krasnopeeva, E.; Sinjab, F.; Pilizota, T.; Kim, M. Active efflux leads to heterogeneous dissipation of proton motive force by protonophores in bacteria. mBio 2021, 12, e0067621. [Google Scholar] [CrossRef] [PubMed]
  33. Radlinski, L.C.; Rowe, S.E.; Brzozowski, R.; Wilkinson, A.D.; Huang, R.; Eswara, P.; Conlon, B.P. Chemical induction of aminoglycoside uptake overcomes antibiotic tolerance and resistance in Staphylococcus aureus. Cell Chem. Biol. 2019, 26, 1355–1364.e1354. [Google Scholar] [CrossRef]
  34. Weston, N.; Sharma, P.; Ricci, V.; Piddock, L.J.V. Regulation of the AcrAB-TolC efflux pump in Enterobacteriaceae. Res. Microbiol. 2018, 169, 425–431. [Google Scholar] [CrossRef]
  35. Yamasaki, S.; Zwama, M.; Yoneda, T.; Hayashi-Nishino, M.; Nishino, K. Drug resistance and physiological roles of RND multidrug efflux pumps in Salmonella enterica, Escherichia coli and Pseudomonas aeruginosa. Microbiology 2023, 169, 001322. [Google Scholar] [CrossRef] [PubMed]
  36. Du, D.; Wang-Kan, X.; Neuberger, A.; van Veen, H.W.; Pos, K.M.; Piddock, L.J.V.; Luisi, B.F. Multidrug efflux pumps: Structure, function and regulation. Nat. Rev. Microbiol. 2018, 16, 523–539. [Google Scholar] [CrossRef]
  37. Jang, S. AcrAB-TolC, a major efflux pump in Gram negative bacteria: Toward understanding its operation mechanism. BMB Rep. 2023, 56, 326–334. [Google Scholar] [CrossRef] [PubMed]
  38. Webber, M.A.; Bailey, A.M.; Blair, J.M.A.; Morgan, E.; Stevens, M.P.; Hinton, J.C.D.; Ivens, A.; Wain, J.; Piddock, L.J.V. The global consequence of disruption of the AcrAB-TolC efflux pump in Salmonella enterica includes reduced expression of SPI-1 and other attributes required to infect the host. J. Bacteriol. 2009, 191, 4276–4285. [Google Scholar] [CrossRef]
  39. Klenotic, P.A.; Moseng, M.A.; Morgan, C.E.; Yu, E.W. Structural and functional diversity of resistance-nodulation-cell division transporters. Chem. Rev. 2021, 121, 5378–5416. [Google Scholar] [CrossRef]
  40. Sharma, A.; Gupta, V.K.; Pathania, R. Efflux pump inhibitors for bacterial pathogens: From bench to bedside. Indian J. Med. Res. 2019, 149, 129–145. [Google Scholar]
  41. Yu, E.W.; Aires, J.R.; McDermott, G.; Nikaido, H. A periplasmic drug-binding site of the AcrB multidrug efflux pump: A crystallographic and site-directed mutagenesis study. J. Bacteriol. 2005, 187, 6804–6815. [Google Scholar] [CrossRef] [PubMed]
  42. Vargiu, A.V.; Nikaido, H. Multidrug binding properties of the AcrB efflux pump characterized by molecular dynamics simulations. Proc. Natl. Acad. Sci. USA 2012, 109, 20637–20642. [Google Scholar] [CrossRef] [PubMed]
  43. Li, X.Z.; Plesiat, P.; Nikaido, H. The challenge of efflux-mediated antibiotic resistance in Gram-negative bacteria. Clin. Microbiol. Rev. 2015, 28, 337–418. [Google Scholar] [CrossRef] [PubMed]
  44. Eaves, D.J.; Ricci, V.; Piddock, L.J.V. Expression of acrB, acrF, acrD, marA, and soxS in Salmonella enterica serovar Typhimurium: Role in multiple antibiotic resistance. Antimicrob. Agents Chemother. 2004, 48, 1145–1150. [Google Scholar] [CrossRef]
  45. Peng, B.; Su, Y.-b.; Li, H.; Han, Y.; Guo, C.; Tian, Y.-M.; Peng, X.-X. Exogenous alanine and/or glucose plus kanamycin kills antibiotic-resistant bacteria. Cell Metab. 2015, 21, 249–262. [Google Scholar] [CrossRef] [PubMed]
  46. Harikishore, A.; Mathiyazakan, V.; Pethe, K.; Grüber, G. Novel targets and inhibitors of the Mycobacterium tuberculosis cytochrome bd oxidase to foster anti-tuberculosis drug discovery. Expert Opin. Drug Discov. 2023, 18, 917–927. [Google Scholar] [CrossRef]
  47. Grossman, T.H. Tetracycline antibiotics and resistance. Cold Spring Harb. Perspect. Med. 2016, 6, a025387. [Google Scholar] [CrossRef]
  48. Zhou, G.; Wang, Q.; Wang, Y.; Wen, X.; Peng, H.; Peng, R.; Shi, Q.; Xie, X.; Li, L. Outer membrane porins contribute to antimicrobial resistance in Gram-negative bacteria. Microorganisms 2023, 11, 1690. [Google Scholar] [CrossRef]
  49. Uddin, M.J.; Jeon, G.; Ahn, J. Variability in the adaptive response of antibiotic-resistant Salmonella Typhimurium to environmental stresses. Microb. Drug Resist. 2019, 25, 182–192. [Google Scholar] [CrossRef]
  50. Bruni, G.N.; Kralj, J.M. Membrane voltage dysregulation driven by metabolic dysfunction underlies bactericidal activity of aminoglycosides. eLife 2020, 9, e58706. [Google Scholar] [CrossRef]
  51. Farha, M.A.; Verschoor, C.P.; Bowdish, D.; Brown, E.D. Collapsing the proton motive force to identify synergistic combinations against Staphylococcus aureus. Chem. Biol. 2013, 20, 1168–1178. [Google Scholar] [CrossRef] [PubMed]
  52. Wu, S.-C.; Han, F.; Song, M.-R.; Chen, S.; Li, Q.; Zhang, Q.; Zhu, K.; Shen, J.-Z. Natural flavones from Morus alba against methicillin-resistant Staphylococcus aureus via targeting the proton motive force and membrane permeability. J. Agric. Food Chem. 2019, 67, 10222–10234. [Google Scholar] [CrossRef]
  53. Amaral, L.; Martins, A.; Spengler, G.; Molnar, J. Efflux pumps of Gram-negative bacteria: What they do, how they do it, with what and how to deal with them. Front. Pharmacol. 2014, 4, 168. [Google Scholar] [CrossRef] [PubMed]
  54. Mulkidjanian, A.Y. Proton in the well and through the desolvation barrier. Biochim. Byophys. Acta 2006, 1757, 415–427. [Google Scholar] [CrossRef]
  55. Black, P.A.; Warren, R.M.; Louw, G.E.; van Helden, P.D.; Victor, T.C.; Kana, B.D. Energy metabolism and drug efflux in Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 2014, 58, 2491–2503. [Google Scholar] [CrossRef] [PubMed]
  56. Capita, R.; Riesco-Pelaez, F.; Alonso-Hernando, A.; Alonso-Calleja, C. Exposure of Escherichia coli ATCC 12806 to sublethal concentrations of food-grade biocides influences its ability to form biofilm, resistance to antimicrobials, and ultrastructure. Appl. Environ. Microbiol. 2014, 80, 1268–1280. [Google Scholar] [CrossRef]
  57. CLSI. M07-A10. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically. In Approved Method of Analysis of CLSI, 10th ed.; Clinical and Laboratory Standards Institute (CLSI): Wayne, PA, USA, 2015. [Google Scholar]
  58. Livak, K.J.; Schmittgen, T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2−ΔΔCT Method. Methods 2001, 25, 402–408. [Google Scholar] [CrossRef]
  59. Dawan, J.; Uddin, M.J.; Ahn, J. Development of de novo resistance in Salmonella Typhimurium treated with antibiotic combinations. FEMS Microbiol. Lett. 2019, 366, fnz127. [Google Scholar] [CrossRef]
  60. Uddin, M.J.; Ahn, J. Characterization of β-lactamase- and efflux pump-mediated multiple antibiotic resistance in Salmonella Typhimurium. Food Sci. Biotechnol. 2018, 27, 921–928. [Google Scholar] [CrossRef]
Antibiotics 12 01335 g001
Figure 1. Heat map of fold changes in MICR of ciprofloxacin-resistant Salmonella Typhimurium (STCIP), gentamicin-resistant S. Typhimurium (STGEN), kanamycin-resistant S. Typhimurium (STKAN), and tetracycline-induced resistant S. Typhimurium (STTET) compared to MICWT of S. Typhimurium ATCC 19585 (STWT). Heat map intensities indicate the fold change in MIC compared to that of the untreated STWT; [log2 MICR/MICW]. CET, cefotaxime; CHL, chloramphenicol; GEN, gentamicin; KAN, kanamycin; PMB, polymyxin B; STR, streptomycin, TET; tetracycline; TOB, tobramycin.
Figure 1. Heat map of fold changes in MICR of ciprofloxacin-resistant Salmonella Typhimurium (STCIP), gentamicin-resistant S. Typhimurium (STGEN), kanamycin-resistant S. Typhimurium (STKAN), and tetracycline-induced resistant S. Typhimurium (STTET) compared to MICWT of S. Typhimurium ATCC 19585 (STWT). Heat map intensities indicate the fold change in MIC compared to that of the untreated STWT; [log2 MICR/MICW]. CET, cefotaxime; CHL, chloramphenicol; GEN, gentamicin; KAN, kanamycin; PMB, polymyxin B; STR, streptomycin, TET; tetracycline; TOB, tobramycin.
Antibiotics 12 01335 g001
Antibiotics 12 01335 g002
Figure 2. Relative expression of selected genes in ciprofloxacin-resistant Salmonella Typhimurium (STCIP, Antibiotics 12 01335 i001), gentamicin-resistant S. Typhimurium (STGEN, Antibiotics 12 01335 i002), kanamycin-resistant S. Typhimurium (STKAN, Antibiotics 12 01335 i003), and tetracycline-induced resistant S. Typhimurium (STTET, Antibiotics 12 01335 i004).
Figure 2. Relative expression of selected genes in ciprofloxacin-resistant Salmonella Typhimurium (STCIP, Antibiotics 12 01335 i001), gentamicin-resistant S. Typhimurium (STGEN, Antibiotics 12 01335 i002), kanamycin-resistant S. Typhimurium (STKAN, Antibiotics 12 01335 i003), and tetracycline-induced resistant S. Typhimurium (STTET, Antibiotics 12 01335 i004).
Antibiotics 12 01335 g002
Antibiotics 12 01335 g003
Figure 3. Schematic diagrams depicting AcrAB-TolC efflux pump system (A), outer membrane porin (B), and proton gradient-induced ATP (C).
Figure 3. Schematic diagrams depicting AcrAB-TolC efflux pump system (A), outer membrane porin (B), and proton gradient-induced ATP (C).
Antibiotics 12 01335 g003
Table 1. Antimicrobial properties of antibiotics used in this study.
Table 1. Antimicrobial properties of antibiotics used in this study.
Class AntibioticTarget SiteAntimicrobial Activity
CephemsCefotaxime Cell wallBactericidal
PhenicolsChloramphenicol 50S ribosomal subunitBacteriostatic
FluoroquinolonesCiprofloxacinDNA gyraseBactericidal
AminoglycosidesGentamycin30S ribosomal subunitBactericidal
AminoglycosidesKanamycin 30S ribosomal subunitBactericidal
AminoglycosidesStreptomycin 30S ribosomal subunitBactericidal
AminoglycosidesTobramycin 30S ribosomal subunitBactericidal
GlycopeptidesPolymyxin BCell membraneBactericidal
TetracyclinesTetracycline 30S ribosomal subunitBacteriostatic
Table 2. Minimum inhibitory concentrations (MICs; µg/mL) of selected antibiotics against Salmonella Typhimurium ATCC 19585 (STWT), ciprofloxacin-resistant S. Typhimurium (STCIP), gentamicin-resistant S. Typhimurium (STGEN), kanamycin-resistant S. Typhimurium (STKAN), and tetracycline-induced resistant S. Typhimurium (STTET).
Table 2. Minimum inhibitory concentrations (MICs; µg/mL) of selected antibiotics against Salmonella Typhimurium ATCC 19585 (STWT), ciprofloxacin-resistant S. Typhimurium (STCIP), gentamicin-resistant S. Typhimurium (STGEN), kanamycin-resistant S. Typhimurium (STKAN), and tetracycline-induced resistant S. Typhimurium (STTET).
AntibioticSTWTSTCIPSTGENSTKANSTTET
Cefotaxime0.062510.06250.1250.5
Chloramphenicol0.5324216
Ciprofloxacin0.0156160.00780.01562
Gentamicin84641282
Kanamycin3281282564
Polymyxin B44224
Streptomycin3216102412816
Tetracycline280.5116
Tobramycin1682561288
Table 3. Minimum inhibitory concentrations (MICs; µg/mL) of ciprofloxacin, gentamicin, kanamycin, and tetracycline of ciprofloxacin-resistant Salmonella Typhimurium (STCIP), gentamicin-resistant S. Typhimurium (STGEN), kanamycin-resistant S. Typhimurium (STKAN), and tetracycline-induced resistant S. Typhimurium (STTET) in the absence and presence of CCCP and PAβN.
Table 3. Minimum inhibitory concentrations (MICs; µg/mL) of ciprofloxacin, gentamicin, kanamycin, and tetracycline of ciprofloxacin-resistant Salmonella Typhimurium (STCIP), gentamicin-resistant S. Typhimurium (STGEN), kanamycin-resistant S. Typhimurium (STKAN), and tetracycline-induced resistant S. Typhimurium (STTET) in the absence and presence of CCCP and PAβN.
StrainAntibioticEfflux Pump Inhibitor
NoCCCPPAβN
STCIPCiprofloxacin16162
STGENGentamicin646464
STKANKanamycin256256256
STTETTetracycline326432
Table 4. Primers used for real-time RT-PCR analysis.
Table 4. Primers used for real-time RT-PCR analysis.
GeneMolecular FunctionPrimes SequenceReferences
16s rRNAReference geneF: AGGCCTTCGGGTTGTAAAGT
R: GTTAGCCGGTGCTTCTTCTG		[59]
acrAMultidrug efflux pumpF: AAAACGGCAAAGCGAAGGT
R: GTACCGGACTGCGGGAATT		[59]
acrBMultidrug efflux pumpF: TGAAAAAAATGGAACCGTTCTTC
R: CGAACGGCGTGGTGTCA		[59]
ompCOuter membrane porinsF: TCGCAGCCTGCTGAACCAGAAC
R: ACGGGTTGCGTTATAGGTCTGAG		[60]
ompFOuter membrane porinsF: CGGAATTTATTGACGGCAGT
R: GAGATAAAAAAACAGGACCG		[60]
ramATranscriptional activatorF: CCAGAAGGTGTATGATATTTGTCTCAAG
R: GGTTGAACGTGCGGGTAAA		[60]
tolCMultidrug efflux pumpF: GCCCGTGCGCAATATGAT
R: CCGCGTTATCCAGGTTGTTG		[59]
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

Share and Cite

MDPI and ACS Style

Hasan, M.; Wang, J.; Ahn, J. Ciprofloxacin and Tetracycline Resistance Cause Collateral Sensitivity to Aminoglycosides in Salmonella Typhimurium. Antibiotics 2023, 12, 1335. https://doi.org/10.3390/antibiotics12081335

AMA Style

Hasan M, Wang J, Ahn J. Ciprofloxacin and Tetracycline Resistance Cause Collateral Sensitivity to Aminoglycosides in Salmonella Typhimurium. Antibiotics. 2023; 12(8):1335. https://doi.org/10.3390/antibiotics12081335

Chicago/Turabian Style

Hasan, Mahadi, Jun Wang, and Juhee Ahn. 2023. "Ciprofloxacin and Tetracycline Resistance Cause Collateral Sensitivity to Aminoglycosides in Salmonella Typhimurium" Antibiotics 12, no. 8: 1335. https://doi.org/10.3390/antibiotics12081335

Note that from the first issue of 2016, this journal uses article numbers instead of page numbers. See further details here.

Article Metrics

Back to TopTop